Pasithea’s NF1 Drug PAS-004 Shows Positive PK Data in Trial
PAS-004’s new tablet showed linear, dose-proportional PK with a long half-life (~57 hours) and tight peak–trough control at steady...
New Data Highlights Zio Performance in an Asian Population
In a real-world analysis of 408,470 U.S. patients monitored with iRhythm’s Zio long-term continuous ECG service, median wear time...
Annovis Links Amyloid to Faster Decline in Parkinson’s
Annovis reported that in its Phase 3 study in early Parkinson’s disease (NCT05357989), buntanetap halted cognitive decline across the...
Eledon Reports Preliminary Tegoprubart Data in Diabetes Trial
In an investigator-initiated islet transplant study in type 1 diabetes, 6 of 6 patients achieved insulin independence on a...
Promising New Padeliporfin Phase 3 Data for UTUC Revealed
Padeliporfin vascular targeted photodynamic therapy produced a 73% complete response rate (27 of 37 evaluable patients) with a generally...
FDA Approves Eylea HD for RVO and Macular Edema Treatment
In the Phase 3 QUASAR trial, EYLEA HD (aflibercept 8 mg) dosed every eight weeks after either three or...
TLX250-CDX Impacts Decisions for Indeterminate Renal Masses
In a post-hoc analysis of 294 patients with indeterminate renal masses, TLX250-CDx (89Zr-DFO-girentuximab) PET/CT would have changed clinical management...
Promising Diabetic Ulcer Treatment Enters Clinical Trial
FibroBiologics will enroll 120 patients across 10 Australian sites in a randomized Phase 1/2 trial of CYWC628, a topically...
FDA Approves Spryte’s Pivotal Aneurysm Imaging Trial
Spryte Medical secured FDA IDE approval to launch INSYTE, a pivotal trial evaluating its neuro optical coherence tomography system...
ACRP Honored with Bronze Prize at 5th Anthem Awards
The Association of Clinical Research Professionals secured a Bronze in the Health: Global Awareness category at the 5th Anthem...